130 related articles for article (PubMed ID: 15867944)
21. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
Guth BD; Müller TH
Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs.
Meade CJ; Muacevic G; Ward P; Soyka R
Jpn J Pharmacol; 1996 Jun; 71(2):119-27. PubMed ID: 8835638
[TBL] [Abstract][Full Text] [Related]
23. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
[TBL] [Abstract][Full Text] [Related]
24. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791
[TBL] [Abstract][Full Text] [Related]
25. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Cherdon C; Rolin S; Hanson J; Ooms A; de Leval L; Drion P; Michiels C; Pirotte B; Masereel B; Sakalihassan N; Defraigne JO; Dogné JM
Prostaglandins Other Lipid Mediat; 2011 Apr; 94(3-4):124-32. PubMed ID: 21397034
[TBL] [Abstract][Full Text] [Related]
26. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
[TBL] [Abstract][Full Text] [Related]
27. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
[TBL] [Abstract][Full Text] [Related]
28. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
[TBL] [Abstract][Full Text] [Related]
29. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
30. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
31. A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors.
Michaux C; Dogné JM; Rolin S; Masereel B; Wouters J; Durant F
Eur J Med Chem; 2003; 38(7-8):703-10. PubMed ID: 12932901
[TBL] [Abstract][Full Text] [Related]
32. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
[TBL] [Abstract][Full Text] [Related]
33. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Dogné JM; Norberg B; Durant F; Masereel B
Acta Crystallogr C; 2002 Oct; 58(Pt 10):o621-3. PubMed ID: 12359948
[TBL] [Abstract][Full Text] [Related]
34. BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.
Rolin S; Hanson J; Vastersaegher C; Cherdon C; Pratico D; Masereel B; Dogne JM
Prostaglandins Other Lipid Mediat; 2007 Aug; 84(1-2):14-23. PubMed ID: 17643884
[TBL] [Abstract][Full Text] [Related]
35. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
36. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction.
Buccellati C; Ciceri P; Ballerio R; Casagrande C; Folco G; Nicosia S
Eur J Pharmacol; 2002 May; 443(1-3):133-41. PubMed ID: 12044803
[TBL] [Abstract][Full Text] [Related]
38. Effects of U-46619 on pulmonary hemodynamics before and after administration of BM-573, a novel thromboxane A2 inhibitor.
Lambermont B; Kolh P; Dogné JM; Ghuysen A; Tchana-Sato V; Morimont P; Benoit P; Gérard P; Masereel B; Limet R; D'Orio V
Arch Physiol Biochem; 2003 Jul; 111(3):217-23. PubMed ID: 14972743
[TBL] [Abstract][Full Text] [Related]
39. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
40. BM 144: an original thromboxane A2 receptor antagonist derived from torasemide.
Dogné JM; Neven P; Damas J; Fontaine J; Rolin S; De Leval X; Delarge J; Masereel B
J Pharm Belg; 1999; 54(2):57-8. PubMed ID: 10380411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
